Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16682955
Manuvakhova M, et al. (2006) Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. Oncogene 25, 6003-14 16682955
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
LY294002 FGF1 inhibit treatment-induced increase
rapamycin FGF1 inhibit treatment-induced increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
U0126 FGF1 no effect upon treatment-induced increase
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

S434-p - p70S6K (human)
Modsite: sFEPKIRsPRRFIGs SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S434‑p, p70S6K iso2 (human): S411‑p, p70S6K (mouse): S434‑p, p70S6K (rat): S434‑p, p70S6K iso2 (rat): S411‑p, p70S6K (fruit fly): S418‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) inhibit treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)

Y317-p - SHC1 iso2 (human)
Modsite: ELFDDPSyVNVQNLD SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y427‑p, SHC1 iso2 (human): Y317‑p, SHC1 iso3 (human): Y272‑p, SHC1 iso6 (human): Y428‑p, SHC1 iso7 (human): Y318‑p, SHC1 (mouse): Y423‑p, SHC1 iso2 (mouse): Y313‑p, SHC1 iso3 (mouse): Y268‑p, SHC1 (rat): Y423‑p, SHC1 iso2 (rat): Y313‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
FGF1 FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)
heregulin increase
heregulin FRS2 (human) no effect upon treatment-induced increase dominant negative (PTB domain only)